One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study.
J Nephrol
; 18(2): 136-40, 2005.
Article
en En
| MEDLINE
| ID: mdl-15944996
ABSTRACT
Angiotensin converting-enzyme inhibition (ACEI) is a widely accepted treatment during established renal diseases and beneficial effects have also been reported in IgA nephropathy (IgAN). Immunosuppression with myco-phenolate mofetil (MMF) has recently been introduced in the treatment of immune-mediated renal diseases showing promising results. Preliminary clinical reports are also suggestive that MMF is effective in severe forms of IgAN. We propose a randomised prospective trial aimed to compare long-term renal survival of early IgAN in the course of ACEI therapy with or without MMF immunosuppression.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Proyectos de Investigación
/
Inhibidores de la Enzima Convertidora de Angiotensina
/
Glomerulonefritis por IGA
/
Inmunosupresores
/
Ácido Micofenólico
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Child
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Nephrol
Asunto de la revista:
NEFROLOGIA
Año:
2005
Tipo del documento:
Article